Skip to main content

Drug Interactions between Brilinta and Plavix

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

clopidogrel ticagrelor

Applies to: Plavix (clopidogrel) and Brilinta (ticagrelor)

MONITOR: The concomitant use of ticagrelor with other platelet inhibitors, anticoagulants, thrombolytic agents, or nonsteroidal anti-inflammatory drugs may increase the risk of bleeding.

MANAGEMENT: Caution is recommended when these drugs are used concomitantly with ticagrelor or within 24 hours of ticagrelor dosing. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.

References

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. "Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals (2011):

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Adp receptor antagonists

Therapeutic duplication

The recommended maximum number of medicines in the 'ADP receptor antagonists' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'ADP receptor antagonists' category:

  • Brilinta (ticagrelor)
  • Plavix (clopidogrel)

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer